BrainsWay Set to Announce Q2 2025 Financial Results
BURLINGTON, Mass. and JERUSALEM, recent reports indicate that BrainsWay Ltd. (NASDAQ: BWAY), a leading company in noninvasive neurostimulation treatments for mental health, is gearing up to unveil its financial results for the second quarter of 2025. This announcement will coincide with a deeper look at their operational highlights before U.S. markets open on the scheduled date.
Conference Call and Webcast Details
Following the release of the financial results, BrainsWay will hold a live conference call and webcast. This event is set for 8:30 AM Eastern Time. Participants can dial in using the United States number 1-877-300-8521, or internationally at 1-412-317-6026. In Israel, the contact number is 1-80-921-2373. Don’t forget to note the conference ID: 10201287, which will be necessary for attendees to enter the call.
Accessing the Webcast
The conference call will be streamed live and will also be available for replay for 30 days. To join, interested parties should ensure they are logged on to the BrainsWay’s website at least ten minutes prior to the call. This helps in seamless participation and ensures that all access technicalities are settled before the call begins.
About BrainsWay and Its Mission
Founded in 2003, BrainsWay is committed to enhancing healthcare through its innovative Deep Transcranial Magnetic Stimulation (Deep TMS™) technology designed for mental health disorders. The company prides itself on being the first TMS provider to secure FDA clearance for three indications backed by rigorous clinical studies. These include major depressive disorder, obsessive-compulsive disorder, and smoking addiction, positioning BrainsWay at the forefront of advanced treatment options in the mental health sector.
Driving Innovation in Mental Health
BrainsWay continues to invest in clinical trials aimed at exploring the efficacy of Deep TMS in various psychiatric, neurological, and addiction disorders. This commitment to rigorous scientific validation and proven clinical effectiveness underscores its leadership role in the domain of mental health innovation. Their profound clinical evidence supports their pledge to advance mental health treatments on a global scale.
Future Prospects and Commitment to Accessibility
BrainsWay is devoted to increasing global awareness and access to its therapies. It recognizes the vital importance of making effective treatments available to individuals worldwide suffering from mental health conditions. Their ongoing efforts in research and clinical trials play a significant role in achieving this goal, further solidifying their reputation as pioneers in the field.
Frequently Asked Questions
What is the date of BrainsWay’s financial results announcement?
BrainsWay is set to announce its second quarter 2025 financial results on August 13, 2025.
How can I join the conference call?
You can join the conference call by dialing 1-877-300-8521 for the United States or 1-412-317-6026 for international callers, along with the conference ID: 10201287.
What technology does BrainsWay use for treatment?
BrainsWay employs Deep Transcranial Magnetic Stimulation (Deep TMS™) technology to provide noninvasive treatments for various mental health disorders.
What conditions are currently treated by BrainsWay?
Current indications for BrainsWay’s treatments include major depressive disorder, obsessive-compulsive disorder, and smoking addiction.
How can I find more information about BrainsWay?
For more information regarding BrainsWay and its cutting-edge treatments, please visit their official website to access the latest updates.
